Rossari Biotech Limited announced that its Board of Directors, in a meeting held on December 18, 2025, approved the incorporation of a wholly-owned subsidiary in the Republic of Singapore. This strategic move involves an initial investment of up to USD 10 million, to be disbursed in tranches. The proposed subsidiary, likely to be named Rossari (Singapore) Pte. Limited, aims to enhance the company's global presence and facilitate future international investments and expansion. The incorporation is anticipated to be completed by the fourth quarter of fiscal year 2026 (Q4 FY26), subject to necessary statutory and regulatory approvals. The new entity will be a related party to Rossari Biotech Limited, with all transactions expected to be conducted on an arm's length basis. The industry to which the entity belongs is chemicals and others. The company will hold 100% of the total equity share capital. Further updates will be provided upon the incorporation of the subsidiary.